title: When do bisphosphonates make the most sense?
authors.affiliation: Menzies Research Institute, Hobart, Tasmania, Australia. tania.winzenberg@utas.edu.au
authors.forename: Tania
authors.initials: T
authors.lastname: Winzenberg
authors.forename: Graeme
authors.initials: G
authors.lastname: Jones
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D000068296:Risedronic Acid; D014481:United States; D016387:Women's Health
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid